n=48. Safety primary met. The exploratory efficacy endpoints are what every other AI-bio company will be reading this weekend.
The LabDemo6 min read
Machine-learned ALS targets clear their first human bar.
Lumenfold Bio's Phase II safety primary met. The efficacy signal is the interesting part.
This is a fictional sample story for demonstration.
